Lexington, MA, United States

Trius Therapeutics

triusrx.com
Lexington, MA, United States
SEARCH FILTERS
Time filter
Source Type

Finn J.,Trius Therapeutics
Expert Opinion on Therapeutic Patents | Year: 2013

The two patent applications describe two novel compounds in the benzimidazole class of GyrB/ParE antibacterial agents and multiple phosphate prodrugs derived from these compounds. The new benzimidazole compounds have excellent antibacterial activity on Gram-positive strains. But like previous benzimidazoles, they have limited solubility and are highly protein bound. The phosphate prodrugs offer a drug substance with high aqueous solubility that should aid both intravenous and oral formulations. The potential utility of the prodrugs was demonstrated in efficacy studies. © 2013 Informa UK, Ltd.


Patent
Trius Therapeutics | Date: 2011-06-02

The present disclosure provides compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R^(5), R^(6 )and Z are as described herein. The disclosure also provides pharmaceutical compositions thereof; and methods for inhibiting DHFR activity; and methods for treating cell proliferative diseases, autoimmune disease, inflammatory disease or bacterial, fungal or parasitic infection by administering a compound of Formula I.


Patent
Trius Therapeutics | Date: 2012-03-14

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.


Patent
Trius Therapeutics | Date: 2013-11-25

Methods of preparing a class of oxazolidinones useful to impede bacterial growth are disclosed.


A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the crystalline form may be used in antibiotics.


Patent
Trius Therapeutics | Date: 2014-07-23

Intermediate compounds that are useful in the Synthesis of oxazolidinones that impede bacterial growth are disclosed.


A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included.


Dosage forms or pharmaceutical compositions comprise a compound having the structure of Formula IV:


Patent
Trius Therapeutics and Lawrence Livermore National Laboratory | Date: 2013-09-11

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.


A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included.

Loading Trius Therapeutics collaborators
Loading Trius Therapeutics collaborators